ΔN-p73α accumulates in human neuroblastic tumors

被引:57
作者
Douc-Rasy, S
Barrois, M
Echeynne, M
Kaghad, M
Blanc, E
Raguenez, G
Goldschneider, D
Terrier-Lacombe, MJ
Hartmann, O
Moll, U
Caput, D
Bénard, J
机构
[1] Inst Gustave Roussy, CNRS, UMR 1598, F-94805 Villejuif, France
[2] Inst Gustave Roussy, Dept Biol Clin, F-94805 Villejuif, France
[3] Inst Gustave Roussy, Dept Pathol, F-94805 Villejuif, France
[4] Inst Gustave Roussy, Dept Pediat, F-94805 Villejuif, France
[5] Sanoft Rech, Labege, France
[6] SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA
关键词
D O I
10.1016/S0002-9440(10)64883-3
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Neuroblastic tumors (NTs), occurring in early childhood, display a wide spectrum of differentiation. Recurrent deletions involving the p73 locus are frequently observed in undifferentiated NTs. To address the question of the possible implication of p73 in neuroblastic differentiation, we investigated the status of the expression of this gene in a panel of differentiated and undifferentiated tumors. Although mutations were not found, p 73 transcript profiles differed between undifferentiated and differentiated tumors. The frequency of the transcripts lacking exon 2 (species 1-3) appeared to be higher in undifferentiated than in differentiating and differentiated NTs. In contrast, products from using an alternate promoter (DeltaN-p73) were present in all NTs. in addition, only DeltaN-p73, but not full-length proteins, were detected by immunoblotting, suggesting a greater stability of N-truncated isoforms. Importantly, as in the adrenal medulla, most NTs showed p73-positive immunohistological staining with a cellular distribution and intensity varying according to the neuronal differentiation. Surprisingly, we observed redistribution of p73 from the nucleus to the cytoplasm during neuroblastic differentiation. Our data suggest that, in undifferentiated NTs, a link may exist between the accumulation of DeltaN-p73alpha variants and the "nuclear exclusion" of p53.
引用
收藏
页码:631 / 639
页数:9
相关论文
共 38 条
  • [1] BALDINT E, 1999, ONCOGENE, V18, P3923
  • [2] Induction of neuronal differentiation by p73 in a neuroblastoma cell line
    De Laurenzi, V
    Raschellá, G
    Barcaroli, D
    Annicchiarico-Petruzzelli, M
    Ranalli, M
    Catani, MV
    Tanno, B
    Costanzo, A
    Levrero, M
    Melino, G
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (20) : 15226 - 15231
  • [3] Two new p73 splice variants, γ and δ, with different transcriptional activity
    De Laurenzi, V
    Costanzo, A
    Barcaroli, D
    Terrinoni, A
    Falco, M
    Annicchiarico-Petruzzeli, M
    Levrero, M
    Melino, G
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (09) : 1763 - 1768
  • [4] Di Como CJ, 1999, MOL CELL BIOL, V19, P1438
  • [5] Inactivation of the p53-homologue p73 by the mdm2-oncoprotein
    Dobbelstein, M
    Wienzek, S
    König, C
    Roth, J
    [J]. ONCOGENE, 1999, 18 (12) : 2101 - 2106
  • [6] MICE DEFICIENT FOR P53 ARE DEVELOPMENTALLY NORMAL BUT SUSCEPTIBLE TO SPONTANEOUS TUMORS
    DONEHOWER, LA
    HARVEY, M
    SLAGLE, BL
    MCARTHUR, MJ
    MONTGOMERY, CA
    BUTEL, JS
    BRADLEY, A
    [J]. NATURE, 1992, 356 (6366) : 215 - 221
  • [7] EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO
  • [8] 2-G
  • [9] Transactivation-deficient p73α (p73Δexon2) inhibits apoptosis and competes with p53
    Fillippovich, I
    Sorokina, N
    Gatei, M
    Haupt, Y
    Hobson, K
    Moallem, E
    Spring, K
    Mould, M
    McGuckin, MA
    Lavin, MF
    Khanna, KK
    [J]. ONCOGENE, 2001, 20 (04) : 514 - 522
  • [10] P53 MUTATIONS IN HUMAN CANCERS
    HOLLSTEIN, M
    SIDRANSKY, D
    VOGELSTEIN, B
    HARRIS, CC
    [J]. SCIENCE, 1991, 253 (5015) : 49 - 53